BIB
ProShares Ultra Nasdaq Biotechnology
Price Chart
Latest Quote
$115.27
+4.21 (+3.79%)
Current Price
| Previous Close | $111.06 |
| Open | $110.15 |
| Day High | $115.38 |
| Day Low | $110.15 |
| Volume | 4,587 |
Fund Information
| Quarterly Dividend / Yield | N/A / 0.19% |
| Net Assets | $96.80M |
| Expense Ratio | 0.95% |
| Category | Trading--Leveraged Equity |
| Fund Family | ProShares |
| Net Asset Value | $111.12 |
| Premium/Discount | 3.74% |
| Quarterly Dividend Yield | 0.19% |
| Exchange | NGM |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $109.94 |
| SMA50 | $113.77 |
| SMA200 | $94.25 |
| RSI | 58.09 |
| ATR | 4.7536 |
| Rel Volume | 0.62 |
Performance History
| Week | +1.16% |
| Month | -0.31% |
| Quarter | +16.86% |
| 6 Months | +43.05% |
| YTD | +44.85% |
| Year | +72.52% |
| 3 Years | +169.98% |
| 5 Years | +33.26% |
| 10 Years | +202.92% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $115.27 | 4,600 |
| 2026-10-26 | $111.07 | 3,100 |
| 2026-10-23 | $110.32 | 4,400 |
| 2026-10-22 | $112.85 | 8,000 |
| 2026-10-21 | $114.71 | 26,900 |
| 2026-10-20 | $113.95 | 4,600 |
| 2026-10-19 | $107.09 | 2,300 |
| 2026-10-16 | $105.10 | 8,400 |
| 2026-10-15 | $111.11 | 8,400 |
| 2026-10-14 | $106.82 | 5,500 |
| 2026-10-13 | $103.59 | 6,300 |
| 2026-10-12 | $108.79 | 2,600 |
| 2026-10-09 | $110.98 | 7,400 |
| 2026-10-08 | $105.02 | 10,900 |
| 2026-10-07 | $107.46 | 4,200 |
| 2026-10-06 | $106.90 | 13,600 |
| 2026-10-05 | $112.06 | 9,800 |
| 2026-10-02 | $109.80 | 10,000 |
| 2026-10-01 | $110.47 | 5,100 |
| 2026-09-30 | $115.45 | 3,300 |
| 2026-09-29 | $115.88 | 4,700 |
| 2026-09-28 | $115.63 | 10,000 |
About ProShares Ultra Nasdaq Biotechnology
The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.
đ° Latest News
No news articles available at the moment. Check back later for updates on BIB.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.